A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus - VENT-03-201
Latest Information Update: 07 Oct 2025
At a glance
- Drugs VENT 03 (Primary)
- Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Ventus Therapeutics
Most Recent Events
- 01 Sep 2025 Status changed from planning to not yet recruiting.
- 22 May 2025 According to a Ventus Therapeutics media release, this trial to commence later this year
- 06 Nov 2024 New trial record